Rasch-analysis of Clinical Severity in FSHD
NCT02766985 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 44
Last updated 2018-04-12
Summary
The purpose of this study is to make a standardized and scalable Rasch-built clinical severity scale to help in finding genetic and environmental modifiers of disease in Facioscapulohumeral muscular dystrophy (FSHD).
Conditions
Sponsors & Collaborators
-
National Institutes of Health (NIH)
collaborator NIH -
University of Kansas Medical Center
lead OTHER
Principal Investigators
-
Jeffrey Statland, MD · University of Kansas Medical Center
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-03-31
- Primary Completion
- 2017-04-18
- Completion
- 2017-04-18
Countries
- United States
Study Locations
More Related Trials
-
Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1)
NCT01136304 ·Status: COMPLETED
-
Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy
NCT02603562 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Core Outcome Set for Head, Neck and Respiratory Disease in Mucopolysaccharidosis II
NCT06022380 ·Status: COMPLETED
-
Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)
NCT05397470 ·Status: TERMINATED ·Phase: PHASE3
-
Assessment Of Liver and Spleen Fibrosis in Patients With Gaucher Disease Using Fibroscan
NCT01898325 ·Status: UNKNOWN ·Phase: NA
-
Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension
NCT02531217 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Mucopolysaccharidosis Type II Natural History
NCT03529786 ·Status: COMPLETED
-
Investigating Lysosomal Storage Diseases in Minority Groups
NCT02120235 ·Status: UNKNOWN
-
Survey Study and Records Review of Treatment Outcomes in Freeman-Sheldon Syndrome
NCT01144741 ·Status: TERMINATED
-
LGMD R1 Natural History Study
NCT05618080 ·Status: RECRUITING
-
Study to Detect Unrecognized Mucopolysaccharidosis in Children Visiting Rheumatology, Hand or Skeletal Dysplasia Clinics
NCT01675674 ·Status: TERMINATED
-
Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension
NCT04004000 ·Status: TERMINATED ·Phase: PHASE2
-
A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome
NCT02126995 ·Status: COMPLETED ·Phase: PHASE2
-
A Natural History of Late Onset Tay-Sachs Disease
NCT02851862 ·Status: COMPLETED
-
A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy
NCT06907875 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Respiratory Cathepsins, Proteases Inhibitors and Glycosaminoglycans (GAG) in Mucopolysaccharidosis
NCT04112602 ·Status: COMPLETED
-
Fabry Outcome Survey (FOS)
NCT03289065 ·Status: COMPLETED
-
Investigations Into ISCU Myopathy or Iron Sulfur Scaffold U Protein Myopathy
NCT01547767 ·Status: COMPLETED
-
FRIEDREICH ATAXIA- STEROIDOGENESIS
NCT07123142 ·Status: COMPLETED
-
A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease
NCT06858397 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Endothelial Derived Hyperpolarization Factor and Vascular Control
NCT05176379 ·Status: RECRUITING ·Phase: PHASE4
-
Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease
NCT02489344 ·Status: COMPLETED ·Phase: PHASE2
-
SLSMDS Natural History Study
NCT05029843 ·Status: UNKNOWN
-
Pharmacokinetics, Pharmacodynamics, and Safety of Moss-aGalactosidase A in Patients With Fabry Disease
NCT02995993 ·Status: COMPLETED ·Phase: PHASE1
-
Assess Urine Biomarkers to Predict Nephropathy in Fabry Disease
NCT06065605 ·Status: UNKNOWN